UK/Swedish global bio-pharmaceutical company, AstraZeneca, is strengthening its haematological cancer pipeline with the acquisition of US-based TeneoTwo and its Phase I clinical-stage T-cell engager, TNB-486. AstraZeneca will acquire all outstanding…






